Piper Jaffray Companies reaffirmed their outperform rating on shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) in a research note issued to investors on Friday, April 14th. They currently have a $10.00 price objective on the specialty pharmaceutical company’s stock.
VRX has been the topic of several other research reports. Deutsche Bank AG lowered their price target on shares of Valeant Pharmaceuticals Intl from $20.00 to $19.00 and set a hold rating on the stock in a research report on Tuesday, March 7th. BTIG Research reaffirmed a neutral rating on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, January 11th. Stifel Nicolaus reaffirmed a buy rating and set a $45.00 target price on shares of Valeant Pharmaceuticals Intl in a report on Thursday, February 9th. Barclays PLC reissued a hold rating and issued a $34.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Thursday, February 9th. Finally, Royal Bank of Canada reissued a sector perform rating and issued a $22.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Tuesday, February 28th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and six have issued a buy rating to the stock. Valeant Pharmaceuticals Intl has a consensus rating of Hold and an average target price of $22.35.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded up 0.260% on Friday, hitting $13.505. The stock had a trading volume of 19,834,626 shares. The firm’s market capitalization is $4.70 billion. Valeant Pharmaceuticals Intl has a 12-month low of $8.31 and a 12-month high of $32.75. The company has a 50 day moving average of $10.48 and a 200-day moving average of $13.78.
Valeant Pharmaceuticals Intl (NYSE:VRX) last posted its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.87 by $1.93. Valeant Pharmaceuticals Intl had a negative net margin of 22.17% and a positive return on equity of 43.81%. The company had revenue of $2.11 billion for the quarter, compared to analyst estimates of $2.17 billion. During the same quarter in the previous year, the firm posted ($1.08) earnings per share. The company’s quarterly revenue was down 11.1% compared to the same quarter last year. Equities analysts predict that Valeant Pharmaceuticals Intl will post $3.89 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals Intl’s (VRX) “Outperform” Rating Reiterated at Piper Jaffray Companies” was originally published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.com-unik.info/2017/05/19/valeant-pharmaceuticals-intl-inc-vrx-earns-outperform-rating-from-piper-jaffray-companies-updated-updated-updated.html.
In other Valeant Pharmaceuticals Intl news, Director Pershing Square Capital Manage sold 18,114,432 shares of the business’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $11.00, for a total value of $199,258,752.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Valueact Capital Master Fund, bought 3,000,000 shares of Valeant Pharmaceuticals Intl stock in a transaction on Tuesday, March 14th. The stock was purchased at an average price of $10.82 per share, with a total value of $32,460,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 3,054,000 shares of company stock valued at $33,103,280. 16.37% of the stock is owned by insiders.
Institutional investors have recently bought and sold shares of the stock. Capstone Asset Management Co. increased its position in Valeant Pharmaceuticals Intl by 1.4% in the third quarter. Capstone Asset Management Co. now owns 26,408 shares of the specialty pharmaceutical company’s stock valued at $648,000 after buying an additional 360 shares during the period. Acadian Asset Management LLC increased its position in Valeant Pharmaceuticals Intl by 127.5% in the third quarter. Acadian Asset Management LLC now owns 425,100 shares of the specialty pharmaceutical company’s stock valued at $10,411,000 after buying an additional 238,216 shares during the period. Ausdal Financial Partners Inc. bought a new position in Valeant Pharmaceuticals Intl during the third quarter valued at about $275,000. Commonwealth Equity Services Inc increased its position in Valeant Pharmaceuticals Intl by 17.0% in the third quarter. Commonwealth Equity Services Inc now owns 25,903 shares of the specialty pharmaceutical company’s stock valued at $636,000 after buying an additional 3,760 shares during the period. Finally, Warren Averett Asset Management LLC bought a new position in Valeant Pharmaceuticals Intl during the third quarter valued at about $246,000. Hedge funds and other institutional investors own 64.34% of the company’s stock.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
What are top analysts saying about Valeant Pharmaceuticals Intl Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Valeant Pharmaceuticals Intl Inc and related companies.